Ifabotuzumab

(anti-EphA3)

Recombinant Monoclonal Antibody for the Treatment of cancers

Ifabotuzumab is a first-in-class, monoclonal antibody targeting the EphA3 receptor tyrosine kinase created using Humanigen's proprietary Humaneered® technology.

Building the Potential.

Ifabotuzumab is unique in its potential to attack tumors at their source by killing tumor cells, tumor stromal cells that protect them, and the vasculature that feeds them without killing normal cells. This unique combination of activities may provide the potential to generate durable responses. Ifabotuzumab may have a similar mechanism of action in patients with solid tumors since it targets solid tumor stem cells and their microenvironment.

The first patient has been dosed in an ifabotuzumab clinical trial of patients with glioblastoma multiforme (GBM) at the Olivia Newton-John Cancer Research Institute in Australia. The trial is an Investigator-Sponsored Phase 0/1 radiolabeled imaging trial in GBM, a particularly aggressive and deadly form of brain cancer. According to the investigators, the trial will seek to confirm the safety of ifabotuzumab and potentially determine the best dose to effectively penetrate brain tumors. The investigators expect about 12 patients to participate in the trial, for which eligibility criteria are recurrent GBM and receipt of only one type of chemotherapy for disease recurrence.

Humanigen is exploring partnering opportunities to enable further development of ifabotuzumab in certain solid and hematologic cancers as an antibody-drug conjugate (ADC) and as a CAR-T construct.


Source: Cure Brain Cancer Foundation